Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment
| Autor: | Akitaka Makiyama, Yosuke Kumekawa, Taito Esaki, Toshikazu Moriwaki, Kentaro Yamazaki, Yusuke Niisato, Naotoshi Sugimoto, Yasuhiro Shimada, Shota Fukuoka, Atsuo Takashima, Toshiki Masuishi, Takeshi Suto, Tadamichi Denda, Takeshi Kajiwara, Yukimasa Hatachi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pyrrolidines Colorectal cancer Pyridines Trifluridine Comorbidity Adenocarcinoma chemistry.chemical_compound Japan Internal medicine Regorafenib Medicine Humans Neoplasm Metastasis Tipiracil Aged Retrospective Studies Salvage Therapy business.industry Patient Selection Phenylurea Compounds General Medicine Middle Aged medicine.disease Thrombosis Survival Analysis Progression-Free Survival Discontinuation Venous thrombosis Drug Combinations Treatment Outcome Oncology chemistry Female business Colorectal Neoplasms Thymine medicine.drug |
| Zdroj: | Anticancer research. 41(4) |
| ISSN: | 1791-7530 |
| Popis: | Background/aim In later-line treatment of metastatic colorectal cancer (mCRC), trifluridine/tipiracil is often selected because regorafenib is difficult to use in patients with comorbidities such as thrombosis, hemorrhage, or cardiac events. However, the safety and efficacy of trifluridine/tipiracil in these patients is not clear. Patients and methods The clinical outcomes of trifluridine/tipiracil were retrospectively investigated in patients who were ineligible for regorafenib because of comorbidities. Results Among the 27 patients who received trifluridine/tipiracil, many had comorbidities of deep venous thrombosis or hemorrhage. The median overall survival was 12.4 months, and the median progression-free survival was 2.8 months. The median overall survival was 7.7 months in 19 patients without subsequent regorafenib. Grade 3 or higher toxicities were found in 51% of patients. No treatment discontinuation because of comorbidities was observed. Conclusion Trifluridine/tipiracil can be safely administered while maintaining efficacy in patients who were ineligible for regorafenib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|